| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.72 | $43.17 (0%) | 🛒 Add to cart |
| 90 | $0.67 | $64.76 $60.24 (7%) | 🛒 Add to cart |
| 120 | $0.64 | $86.35 $76.31 (12%) | 🛒 Add to cart |
| 180 | $0.61 | $129.52 $109.44 (16%) | 🛒 Add to cart |
| 270 | $0.59 | $194.29 $159.65 (18%) | 🛒 Add to cart |
| 360 | $0.58
Best per pill | $259.05 $209.85 (19%) | 🛒 Add to cart |
Synonyms
| |||
Similar products
More info:
Tamoxifen: Targeted Estrogen Receptor Modulation for Breast Cancer
Tamoxifen is a selective estrogen receptor modulator (SERM) widely utilized in the management of hormone receptor-positive breast cancer. It functions as an estrogen antagonist in breast tissue, competitively inhibiting estrogen binding to its receptors, thereby impeding the proliferation of malignant cells. Its well-established efficacy profile and extensive clinical history make it a cornerstone of endocrine therapy for both early and advanced disease stages. This agent is also indicated for risk reduction in high-risk populations, underscoring its dual therapeutic and preventive roles.
Altraz: Advanced Aromatase Inhibition for Hormone-Responsive Breast Cancer
Altraz (anastrozole) is a potent, non-steroidal aromatase inhibitor indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. It is also approved for the first-line treatment of advanced or metastatic hormone receptor-positive breast cancer in postmenopausal women. By selectively inhibiting the aromatase enzyme, Altraz significantly reduces estrogen production, a key driver of tumor proliferation in estrogen-dependent malignancies. This targeted mechanism offers a sophisticated endocrine therapy option with a well-established efficacy and safety profile, making it a cornerstone in the management of hormone-sensitive breast cancer.
Arimidex: Advanced Estrogen Control for Breast Cancer Treatment
Arimidex (anastrozole) is a potent, non-steroidal aromatase inhibitor specifically formulated for the treatment of hormone receptor-positive early and advanced breast cancer in postmenopausal women. By selectively inhibiting the aromatase enzyme, Arimidex significantly reduces estrogen production, creating an unfavorable environment for hormone-sensitive tumor growth. This targeted mechanism offers a sophisticated endocrine therapy option with a well-established efficacy and safety profile, making it a cornerstone in modern breast cancer management protocols. Features Active ingredient: Anastrozole 1 mg Pharmaceutical class: Non-steroidal aromatase inhibitor Administration: Oral tablet formulation Bioavailability: Approximately 80-85% following oral administration Half-life: 40-50 hours in postmenopausal women Metabolism: Primarily hepatic via N-dealkylation, hydroxylation, and glucuronidation Excretion: Primarily hepatic (85%) with renal elimination of metabolites Special coating: Film-coated for easier swallowing Benefits Superior disease-free survival rates compared to tamoxifen in early breast cancer Significant reduction in contralateral breast cancer incidence Avoids estrogen agonist effects associated with tamoxifen therapy Favorable long-term safety profile with reduced endometrial cancer risk Convenient once-daily dosing regimen No requirement for corticosteroid supplementation Common use Arimidex is primarily indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.
Aromasin: Advanced Estrogen Control for Breast Cancer Therapy
Aromasin (exemestane) is a steroidal aromatase inactivator specifically designed for the treatment of estrogen receptor-positive breast cancer in postmenopausal women. As a third-generation aromatase inhibitor, it works by permanently binding to the aromatase enzyme, effectively suppressing estrogen production throughout the body. This targeted mechanism offers a sophisticated endocrine therapy option with a well-established efficacy and safety profile, making it a cornerstone in both adjuvant and metastatic treatment settings. Clinical evidence supports its role in significantly reducing recurrence risk and improving survival outcomes.
Estriol: Targeted Hormone Therapy for Symptom Relief
Estriol is a bioidentical estrogen hormone primarily indicated for the management of genitourinary symptoms associated with menopause, such as vaginal dryness, itching, burning, and dyspareunia. As a weak estrogen, it offers localized efficacy with a favorable safety profile due to its selective action on estrogen receptors in urogenital tissues. Available in various formulations including creams, gels, and suppositories, estriol provides a tailored approach to hormone therapy, minimizing systemic absorption while effectively restoring vaginal epithelium and alleviating discomfort.
Femara: Advanced Aromatase Inhibition for Hormone-Sensitive Breast Cancer
Femara (letrozole) is a potent, third-generation nonsteroidal aromatase inhibitor indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. It is also approved for the extended adjuvant treatment of early breast cancer following standard tamoxifen therapy, as well as for the first-line treatment of advanced or metastatic breast cancer in postmenopausal women. By selectively inhibiting the aromatase enzyme, Femara significantly reduces estrogen production, depriving hormone-sensitive tumor cells of their primary growth stimulus.
Fertomid: A Trusted Solution for Ovulation Induction
Fertomid (Clomiphene Citrate) is a first-line oral medication widely prescribed for the treatment of anovulatory infertility in women. As a selective estrogen receptor modulator (SERM), it works by stimulating the pituitary gland to increase the production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which are critical for the development and release of a mature egg. This medication represents a cornerstone in fertility treatment protocols, offering a non-invasive and cost-effective approach to achieving pregnancy.
Fluoxetine: Expert Treatment for Depression and Anxiety Disorders
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) widely prescribed for the management of major depressive disorder, obsessive-compulsive disorder, panic disorder, and bulimia nervosa. As a first-line pharmacological intervention, it functions by increasing serotonin levels in the brain, which helps regulate mood, reduce anxiety, and improve overall emotional stability. Its well-established efficacy, favorable safety profile, and extensive clinical history make it a cornerstone in psychiatric treatment protocols worldwide. Features Active ingredient: Fluoxetine hydrochloride Available in 10 mg, 20 mg, and 40 mg oral capsules, as well as liquid formulation Selective serotonin reuptake inhibitor (SSRI) class Half-life of 4–6 days (longer for its active metabolite norfluoxetine) FDA-approved for multiple psychiatric and behavioral conditions Bioavailability of approximately 72% Peak plasma concentration within 6–8 hours Benefits Effectively alleviates symptoms of major depressive disorder Reduces frequency and intensity of panic attacks Helps manage obsessive-compulsive behaviors and intrusive thoughts Supports recovery in bulimia nervosa by reducing binge-eating and purging behaviors Improves overall mood stability and daily functioning Long half-life supports consistent therapeutic levels and simplifies dosing Common use Fluoxetine is primarily indicated for the treatment of major depressive disorder (MDD) in adults and pediatric patients aged 8 years and older.
Lexapro: Effective SSRI Treatment for Depression and Anxiety
Lexapro (escitalopram oxalate) is a selective serotonin reuptake inhibitor (SSRI) approved by the FDA for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and adolescents. As one of the most widely prescribed antidepressants globally, Lexapro offers a favorable balance of efficacy and tolerability, making it a first-line option for clinicians managing mood and anxiety disorders. Its mechanism of action involves enhancing serotonin activity in the central nervous system, which is critical for regulating mood, emotion, and anxiety.